← Leaderboards
James Kim
Ut Southwestern Medical Center
$3,748,566
Attributed
$3,748,566
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $811K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,748,566 · 3
By mechanism
R01$3,748,566 · 3
Top collaborators
No co-investigators on record.
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Filipa Rijo-Ferreira$2,415,828
- Dawen Zhao$3,249,655
- Elan D Louis$34,798,515
- Lawrence Lum$3,954,131
- Massimo Attanasio$2,404,393
Others in their field
Other Emerging Leaders on “Pathway Interactions”
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Kevin Urdahl · Seattle Children'S Hospital$47,227,116
- Urs Ochsner · Crestone, Inc.$38,569,476
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jeffrey Glenn · Stanford University$26,017,226
Research focus
Pathway InteractionsResearch Clinical TestingProteinsTumor Suppressor ProteinsMalignant NeoplasmsGenesBcl2 GeneMouse ModelMutationCell LineGenetic TranscriptionErinaceidaeMcl1 GeneGrowthCancer Cell LineTumor GrowthRegulationBaseMalignant Neoplasm Of LungGeneticCancer PatientChemotherapyDna BindingBrd2 Gene
Grant awards (10)
Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinoma$387,868
R01 · FY2025 · CA · contact PI
Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinoma$370,338
R01 · FY2024 · CA · contact PI
Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinoma$383,011
R01 · FY2023 · CA · contact PI
Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinoma$378,841
R01 · FY2022 · CA · contact PI
Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinoma$386,971
R01 · FY2021 · CA · contact PI
Targeting vismodegib-resistant tumors using BH3 mimetics$346,985
R01 · FY2020 · CA · contact PI
Targeting vismodegib-resistant tumors using BH3 mimetics$336,575
R01 · FY2019 · CA · contact PI
Targeting vismodegib-resistant tumors using BH3 mimetics$346,985
R01 · FY2018 · CA · contact PI
Chemical disruption of Wnt-mediated signal transduction$464,007
R01 · FY2017 · CA · contact PI
Targeting vismodegib-resistant tumors using BH3 mimetics$346,985
R01 · FY2017 · CA · contact PI